Detail akcie NanoGroup Br online

Business Summary: Nanogroup SA is a Poland-based company engaged in the biotechnology sector. The Company focuses on the investment in, as well as development of advanced biotechnological projects in the areas of cancer prevention, early diagnosis, targeted cancer therapies and ontological rehabilitation. Its projects portfolio includes NanoVelos, which is responsible for the creation of drug delivery system for proven oncologic medicines to optimize their performance; NanoSanguis, which develops artificial blood to keep alive patients wounded in accidents, as well as a system, named Organ farm, to preserve human organs ex vivo, and NanoThea, which is dedicated to technology that detects cancer cells in early stage.
Financial Summary: BRIEF: For the three months ended 31 March 2026, Nanogroup SA revenues was not reported. Net loss increased 24% to PLN2.2M. Higher net loss reflects External Expense increase of 47% to PLN1.1M (expense), Labor & Related Expenses in SGA increase of 23% to PLN990K (expense), Financial Income decrease from PLN68K (income) to PLN0K. Basic Earnings per Share excluding Extraordinary Items increased from -PLN0.06 to -PLN0.05.